Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHDXNASDAQ:NTRANYSE:NVTANASDAQ:RDNTNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHDXGenomic Health$63.44$64.79$50.77▼$90.18$2.38B0.91.05 million shsN/ANTRANatera$161.500.0%$160.34$92.14▼$183.00$22.05B1.731.43 million shs468,868 shsNVTAInvitae$0.00$0.00$0.02▼$0.02$80K1.5923.72 million shs75 shsRDNTRadNet$56.16+0.9%$56.64$45.00▼$93.65$4.21B1.41684,265 shs251,969 shsVCYTVeracyte$27.51-0.3%$28.10$19.73▼$47.32$2.15B2.07918,675 shs445,469 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHDXGenomic Health0.00%0.00%0.00%0.00%0.00%NTRANatera0.00%-3.85%-1.38%+16.81%+43.25%NVTAInvitae0.00%0.00%0.00%0.00%-57.14%RDNTRadNet0.00%-1.68%-4.25%+13.94%-5.82%VCYTVeracyte0.00%+0.47%+0.18%-6.84%+27.78%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHDXGenomic HealthN/AN/AN/AN/AN/AN/AN/AN/ANTRANatera2.1396 of 5 stars2.52.00.00.03.42.50.6NVTAInvitaeN/AN/AN/AN/AN/AN/AN/AN/ARDNTRadNet3.6763 of 5 stars2.82.00.04.62.12.50.0VCYTVeracyte3.6112 of 5 stars3.41.00.04.32.50.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHDXGenomic Health 0.00N/AN/AN/ANTRANatera 3.00Buy$184.6314.32% UpsideNVTAInvitae 0.00N/AN/AN/ARDNTRadNet 3.50Strong Buy$69.6023.93% UpsideVCYTVeracyte 2.70Moderate Buy$40.9048.67% UpsideCurrent Analyst Ratings BreakdownLatest GHDX, NTRA, NVTA, VCYT, and RDNT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/13/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$69.006/12/2025RDNTRadNetB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy5/15/2025NTRANateraPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.005/9/2025NTRANateraUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$211.00 ➝ $218.005/9/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.005/8/2025VCYTVeracyteUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$49.00 ➝ $42.005/8/2025VCYTVeracyteNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$51.00 ➝ $41.004/11/2025RDNTRadNetTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$88.00 ➝ $74.004/10/2025NTRANateraBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$200.00 ➝ $160.004/9/2025VCYTVeracyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $37.00(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHDXGenomic Health$394.11M6.05$1.45 per share43.76$7.48 per share8.48NTRANatera$1.70B13.00N/AN/A$9.05 per share17.85NVTAInvitae$481.58M0.00N/AN/A$0.42 per share0.00RDNTRadNet$1.83B2.30$3.48 per share16.14$15.31 per share3.67VCYTVeracyte$445.76M4.83$1.04 per share26.53$15.17 per share1.81Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHDXGenomic Health$25.68M$1.0560.4236.88N/A12.81%19.62%14.89%N/ANTRANatera-$190.43M-$1.47N/AN/AN/A-10.36%-18.29%-11.68%8/14/2025 (Estimated)NVTAInvitae-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/ARDNTRadNet$2.79M-$0.43N/A105.96N/A-1.73%1.41%0.48%8/6/2025 (Estimated)VCYTVeracyte$24.14M$0.4167.1038.21N/A7.13%6.14%5.60%8/5/2025 (Estimated)Latest GHDX, NTRA, NVTA, VCYT, and RDNT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NTRANatera-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHDXGenomic HealthN/AN/AN/AN/AN/ANTRANateraN/AN/AN/AN/AN/ANVTAInvitaeN/AN/AN/AN/AN/ARDNTRadNetN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHDXGenomic Health0.155.965.96NTRANateraN/A3.873.74NVTAInvitaeN/A2.392.25RDNTRadNet0.872.012.01VCYTVeracyteN/A5.104.78Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHDXGenomic Health93.87%NTRANatera99.90%NVTAInvitae61.28%RDNTRadNet77.90%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipGHDXGenomic Health31.30%NTRANatera7.60%NVTAInvitae0.74%RDNTRadNet5.60%VCYTVeracyte1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHDXGenomic Health82937.59 millionN/AOptionableNTRANatera4,434136.55 million126.17 millionOptionableNVTAInvitae1,700267.01 million284.37 millionOptionableRDNTRadNet11,02175.03 million70.83 millionOptionableVCYTVeracyte79078.32 million77.22 millionOptionableGHDX, NTRA, NVTA, VCYT, and RDNT HeadlinesRecent News About These CompaniesWealth Enhancement Advisory Services LLC Grows Holdings in Veracyte, Inc. (NASDAQ:VCYT)July 6 at 3:14 AM | marketbeat.comVeracyte, Inc. (VCYT) - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comVeracyte, Inc. (NASDAQ:VCYT) Shares Sold by Sumitomo Mitsui Trust Group Inc.July 1, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Downgraded by Wall Street Zen to "Hold"June 29, 2025 | americanbankingnews.comWall Street Zen Downgrades Veracyte (NASDAQ:VCYT) to HoldJune 28, 2025 | marketbeat.comAMI Asset Management Corp Has $1.44 Million Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)June 26, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Moderate Buy" from AnalystsJune 23, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) shareholders have earned a 19% return over the last yearJune 20, 2025 | finance.yahoo.comGAMMA Investing LLC Purchases 18,840 Shares of Veracyte, Inc. (NASDAQ:VCYT)June 19, 2025 | marketbeat.comCathie Wood’s ARK buys BWX stock, sells Adaptive BiotechJune 18, 2025 | investing.comExchange Traded Concepts LLC Increases Stake in Veracyte, Inc. (NASDAQ:VCYT)June 17, 2025 | marketbeat.comVeracyte, Inc. (NASDAQ:VCYT) Shares Purchased by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Stock Rating Upgraded by Wall Street ZenJune 14, 2025 | marketbeat.comVeracyte (NASDAQ:VCYT) Shares Down 4.8% - Should You Sell?June 12, 2025 | marketbeat.comVeracyte (VCYT) Fell Despite Reporting Revenue Growth and Improved ProfitabilityJune 9, 2025 | msn.comCathie Wood's Ark Invest Loads Up On Veracyte, Offloads 3D SystemsJune 7, 2025 | benzinga.comInsider Selling: John Leite Sells Shares of Veracyte Inc (VCYT)June 6, 2025 | gurufocus.comVeracyte (VCYT) Down 13.6% Since Last Earnings Report: Can It Rebound?June 6, 2025 | msn.comCathie Wood’s ARK sells Palantir and Roblox, buys Veracyte and GuardantJune 4, 2025 | investing.comVeracyte (VCYT) Shares Pulled Back Despite Beating ExpectationsJune 3, 2025 | msn.comVeracyte, Inc. (VCYT) Presents Breakthrough Genomic Data to Predict Cancer Therapy Response at ASCOMay 28, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab: Latest Catalysts Bolster the Bull CaseBy Ryan Hasson | July 3, 2025View Rocket Lab: Latest Catalysts Bolster the Bull Case3 Blockchain Stocks to Profit in a Decentralized WorldBy Chris Markoch | June 24, 2025View 3 Blockchain Stocks to Profit in a Decentralized WorldScience Applications International Is a Wicked Hot Buy in JuneBy Thomas Hughes | June 9, 2025View Science Applications International Is a Wicked Hot Buy in JuneForget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerBy Jeffrey Neal Johnson | June 19, 2025View Forget the Fed: Home Depot Is the Real Gauge of the U.S. ConsumerGeospace Stock Skyrockets After Major Petrobras ContractBy Jeffrey Neal Johnson | June 24, 2025View Geospace Stock Skyrockets After Major Petrobras ContractGHDX, NTRA, NVTA, VCYT, and RDNT Company DescriptionsGenomic Health NASDAQ:GHDXGenomic Health, Inc., a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions. It offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. The company also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy; Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk prostate cancer, as well as to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score; and Oncotype DX AR-V7 nucleus detect tests for men with metastatic castration-resistant prostate cancer. In addition, it develops Oncoytpe DXi IVD breast recurrence score test; and Oncotype DX GPS test. The company offers its products through a network of distributors. Genomic Health, Inc. has license and development agreement with Biocartis N.V. to develop and commercialize an in vitro diagnostic of the Oncotype DX breast cancer test; collaboration agreement with Epic Sciences, Inc. to commercializeAR-V7 Nucleus Detect test; and license and development agreement with Cleveland Diagnostics, Inc. to develop and commercialize new prostate cancer tests. The company was founded in 2000 and is based in Redwood City, California.Natera NASDAQ:NTRA$161.50 -0.07 (-0.04%) Closing price 07/3/2025 03:54 PM EasternExtended Trading$161.50 0.00 (0.00%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.Invitae NYSE:NVTAInvitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.RadNet NASDAQ:RDNT$56.16 +0.51 (+0.92%) Closing price 07/3/2025 02:28 PM EasternExtended Trading$56.16 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.Veracyte NASDAQ:VCYT$27.51 -0.07 (-0.25%) Closing price 07/3/2025 03:36 PM EasternExtended Trading$27.67 +0.16 (+0.58%) As of 07/3/2025 04:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
